CNSP US18978H1023

Rapport

Vertraagde tijd Nasdaq - 22:00 16-08-2022
0.2400	USD		-7.30%

15/08	CNS Pharmaceuticals, Inc. Geeft een klinische update van zijn anti-kankermedicijnkandidaten die momenteel in ontwikkeling zijn voor de behandeling van primaire en uitgezaaide hersen- en CZS-kanker	CI
12/08	CNS Pharmaceuticals, Inc. Rapporteert Winstresultaten voor het Tweede Kwartaal en de Zes Maanden Geëindigd op 30 Juni, 2022	CI
23/06	CNS Pharmaceuticals krijgt FDA-goedkeuring voor uitbreiding van het aantal patiënten dat in aanmerking komt voor een proef met hersenkankerbehandeling; aandelen stijgen	MT

Nieuws

Aanbevelingen van analisten

Andere talen

Persberichten

Officiële publicaties

Sectornieuws

Nieuws in andere talen op CNS PHARMACEUTICALS, INC.

2020	CNS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Financial Statemen..
2020	WPD Pharmaceuticals Inc. Partners with CNS Pharmaceuticals, Inc. on Drug Development fo..
2020	CNS PHARMACEUTICALS : Signs Agreement with WPD Pharmaceuticals to Develop Drug Candidates ..
2020	CNS Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter and Year Ende..
2020	CNS PHARMACEUTICALS : Management's Discussion and Analysis of Financial Condition and Resu..
2020	CNS PHARMACEUTICALS : Announces Business Highlights and 2019 Fourth Quarter Financial Resu..
2020	CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020	CNS PHARMACEUTICALS : to Report Fourth Quarter 2019 Financial Results on March 12, 2020
2020	WPD Pharmaceuticals’ Brain Cancer Drug Received Positive FDA Pre-IND Guidance
2020	CNS PHARMACEUTICALS : Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains ..
2020	CNS Pharmaceuticals Announces Brain Cancer Patient from Berubicin Phase 1 Trial Remains..
2020	CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020	CNS PHARMACEUTICALS : to Ring Nasdaq Stock Market Opening Bell on March 3
2020	WPD Pharmaceuticals Inc. Plans to Initiate A Phase I Clinical Trial for Berubicin in Pe..
2020	CNS PHARMACEUTICALS : Announces Collaboration with European Partner to Expand Clinical Tri..
2020	CNS Pharmaceuticals, Inc. Announces Plan to Initiate Phase I Clinical Trial for Berubic..
2020	CNS PHARMACEUTICALS : Announces Completion of GMP Manufacturing
2020	CNS Pharmaceuticals, Inc. Announces Completion of GMP Manufacturing
2020	CNS PHARMACEUTICALS : Completes Pilot Manufacturing Steps Pursuant to FDA Pre-IND Guidance
2020	CNS PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement, Regulation FD Disc..
2020	CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020	CNS PHARMACEUTICALS : Announces Contract with International GMP Manufacturer for Productio..
2020	CNS PHARMACEUTICALS, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (f..
2020	CNS PHARMACEUTICALS : Licenses Breakthrough Technology from MD Anderson, Doubling its Drug..
2019	CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Growth Index
2019	CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Value Index
2019	CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to Russell Microcap Index
2019	CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to S&P TMI Index
2019	CNS PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESU..
2019	Cns Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter Ended Septembe..
2019	CNS PHARMACEUTICALS : Partnered with Anthem Biosciences Pvt. Ltd. in Preparation for Upcom..
2019	CNS Pharmaceuticals Partners with Anthem Biosciences Pvt. Ltd. in Preparation for Upcom..
2019	CNS PHARMACEUTICALS : ' Berubicin Awarded $5.8 Million Non-Dilutive Grant from EU/Polish N..
2019	CNS PHARMACEUTICALS : Received Positive FDA Pre-IND Guidance for Berubicin
2019	CNS Pharmaceuticals, Inc. Receives Positive FDA Pre-IND Guidance for Berubicin
2019	CNS PHARMACEUTICALS : to Participate in the 8th Annual ROTH Deer Valley Corporate Access E..
2019	CNS PHARMACEUTICALS : to Participate in 12th Annual LD Micro Main Event Conference
2019	CNS PHARMACEUTICALS : Entered $2.0 Million Sublicense Agreement with WPD Pharmaceuticals
2019	CNS Pharmaceuticals Enters $2.0 Million Dollar Sublicense Agreement with WPD Pharmaceut..
2019	CNS PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)
2019	CNS PHARMACEUTICALS : Announces Full Exercise of Over-Allotment Option
2019	CNS PHARMACEUTICALS : Announces Attendance at the 24th Annual Meeting of the Society of Ne..
2019	CNS PHARMACEUTICALS : Acquired Worldwide Rights for Brain Cancer Drug from Houston Pharmac..
2019	CNS Pharmaceuticals, Inc. Acquired Worldwide Rights for Brain Cancer Drug from Houston ..
2019	CNS Pharmaceuticals, Inc. Announces Executive Changes
2019	CNS PHARMACEUTICALS : Announces Closing Of Initial Public Offering of Common Stock
2019	CNS PHARMACEUTICALS, INC.(NASDAQCM : CNSP) added to NASDAQ Composite Index
2019	CNS Pharmaceuticals, Inc. has completed an IPO in the amount of $8.5 million.
2019	CNS Pharmaceuticals, Inc. has filed an IPO in the amount of $10.625 million.
2019	CNS Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt
2018	CNS Pharmaceuticals, Inc. announced that it has received $0.628558 million in funding
2018	CNS Pharmaceuticals, Inc. announced that it expects to receive $1.07 million in funding

Vorig 1 2 3 4

Volgende evenement op CNS PHARMACEUTICALS, INC.

16/03/23

Boekjaar 2022 Cijferpublicaties (schatting)

De agenda van het bedrijf

Komende gebeurtenissen in de sector

26/10/22	IQVIA HOLDINGS INC. : Q3 2022 Cijferpublicaties (schatting)
27/10/22	ALNYLAM PHARMACEUTICALS, INC. : Q3 2022 Cijferpublicaties (schatting)
27/10/22	SEAGEN INC. : Q3 2022 Cijferpublicaties (schatting)
03/11/22	MODERNA, INC. : Q3 2022 Cijferpublicaties (schatting)

Meer evenementen

Sector

Gezondheidszorg
	Farmaceutisch en medisch onderzoek
		Biotechnologie & Medisch Onderzoek
			Biotechnologie & Medisch Onderzoek
				Biotechnologie & Medisch Onderzoek - Andere